TY - GEN
T1 - Predicting Malignancy in Adnexal Tumors With FAPI PET/CT and FDG PET/CT: A Case Report on a Borderline Ovarian Tumor
AU - Umachanger, Janani Kantharooban
AU - Zacho, Helle Damgaard
AU - Sylvest, Camilla
AU - Frandsen, Anna Poulsgaard
AU - Bentestuen, Morten
N1 - Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2024/10/30
Y1 - 2024/10/30
N2 - A 54-year-old woman presented with a 55 × 64-mm tumor in the ovary with high [18F]FDG uptake on [18F]FDG PET/CT highly suggestive of ovarian cancer. Prior to surgery, the patient underwent [68Ga]-Ga- fibroblast activation protein inhibitor (FAPI)-46 PET/CT, which revealed low [68Ga]-Ga-FAPI-46 tumor uptake. Histopathology revealed a borderline ovarian tumor, which has low malignant potential and a 10-year survival rate greater than 93%. High [18F]FDG uptake is considered a fair predictor of malignancy in adnexal tumors. The present case demonstrates the potential superiority of [68Ga]-Ga-FAPI-46 PET/CT over [18F]-FDG PET/CT in differentiating malignant adnexal tumors from borderline ovarian tumors.
AB - A 54-year-old woman presented with a 55 × 64-mm tumor in the ovary with high [18F]FDG uptake on [18F]FDG PET/CT highly suggestive of ovarian cancer. Prior to surgery, the patient underwent [68Ga]-Ga- fibroblast activation protein inhibitor (FAPI)-46 PET/CT, which revealed low [68Ga]-Ga-FAPI-46 tumor uptake. Histopathology revealed a borderline ovarian tumor, which has low malignant potential and a 10-year survival rate greater than 93%. High [18F]FDG uptake is considered a fair predictor of malignancy in adnexal tumors. The present case demonstrates the potential superiority of [68Ga]-Ga-FAPI-46 PET/CT over [18F]-FDG PET/CT in differentiating malignant adnexal tumors from borderline ovarian tumors.
KW - FAPI
KW - FDG
KW - PET/CT
KW - borderline ovarian tumor
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85208590826&partnerID=8YFLogxK
U2 - 10.1097/RLU.0000000000005537
DO - 10.1097/RLU.0000000000005537
M3 - Case Report
C2 - 39479983
SN - 0363-9762
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
M1 - 10.1097/RLU.0000000000005537
ER -